Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) reported that its Compensation Committee approved inducement equity awards for new Chief Medical Officer Leonardo Nicacio, effective August 16, 2026, under Nasdaq Listing Rule 5635(c)(4). The awards were granted outside Corbus’ stockholder-approved equity plans as a material inducement to his employment.

The package includes a nonstatutory stock option for up to 191,676 shares of common stock at an exercise price of $10.09, with a ten-year term, vesting 25% on the first anniversary and the remaining 75% in equal monthly installments over 36 months, subject to continued service. It also includes 58,333 restricted stock units vesting in four equal annual installments, each RSU converting into one share upon vesting, contingent on continued service.

Positive

• Equity-based inducement package aligns new CMO incentives with shareholder value through 191,676 options and 58,333 RSUs
• Four-year vesting schedules support leadership retention and continuity in clinical strategy
• Nasdaq Rule 5635(c)(4) structure preserves existing stockholder-approved equity plan capacity

Negative

• Potential shareholder dilution from 191,676 new options and 58,333 RSUs if fully vested and exercised

News Explained

The August 16 inducement grants are approved and commenced with employment, but the option requires exercise and the restricted stock units require vesting; shares issued under either award would increase the share count and reduce existing holders’ percentage ownership.

Market reaction after Chief Medical Officer leadership change: CRBP +3.32%

+3.32% $10.43 2.4x vol

15m delay

+3.32% Vs previous close

$10.43 Last Price

$9.59 $10.52 Day Range

$201.63M Market Cap

2.4x Rel. Volume

Following this news, CRBP has gained 3.32%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $10.43. Trading volume is elevated at 2.4x the average, suggesting notable buying interest.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

Recent insider activity was classified as Net Selling across the 90-day context. For this leadership...

Analysis

Recent insider activity was classified as Net Selling across the 90-day context. For this leadership announcement, that platform signal adds a governance risk lens; the active S-3 shelf and equity-award structure are additional financing considerations.

Key Figures

Option shares: 191,676 shares Restricted stock units: 58,333 shares Exercise price: $10.09 +5 more

8 metrics

Option shares 191,676 shares Inducement stock option

Restricted stock units 58,333 shares Inducement grant

Exercise price $10.09 Stock option

Option term 10 years Stock option

Vesting period 4 years Stock option

Initial vesting 25% Original option shares vest on first anniversary

Remaining vesting 75% Option shares vest after the first anniversary

Monthly vesting 36 months Remaining option vesting period

Historical Context

5 past events · Latest: Aug 06 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 06	Earnings report	Negative	+1.8%	Higher net loss and operating expenses accompanied pipeline and cash updates
Aug 04	Clinical milestone	Positive	+5.4%	Last patient completed final CANYON-1 clinical visit ahead of topline data
Jul 28	FDA clearance	Positive	+0.1%	FDA cleared initiation of the TEMPO-1 registrational study
Jul 06	Leadership change	Positive	-2.7%	Company appointed Leonardo Viana Nicacio as Chief Medical Officer
May 26	Clinical data	Negative	-30.3%	Updated data included ocular adverse events and treatment discontinuations

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Corbus's recent positive clinical and regulatory announcements produced mixed outcomes, including both strong gains and substantial declines.

Key Terms

nonstatutory stock option, restricted stock units, nasdaq listing rule 5635(c)(4)

3 terms

nonstatutory stock option financial

"a nonstatutory stock option to purchase up to 191,676 shares"

A nonstatutory stock option (also called a non-qualified stock option) is an employee or contractor right to buy company shares at a set price that does not qualify for special tax treatment. When exercised, the difference between the market price and the set price is treated as ordinary income for the recipient and usually triggers payroll tax and withholding. For investors, these options matter because they create potential share dilution, affect reported compensation costs, and influence the timing of when new shares enter the market—similar to a coupon that lets someone buy stock at a discount but results in an immediate tax bill.

restricted stock units financial

"restricted stock units for 58,333 shares of common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the grant of inducement equity awards outside of the Company's stockholder-approved equity compensation plans to Leonardo Nicacio in connection with his commencement of employment as Chief Medical Officer of the Company. The grants were approved by the Compensation Committee of the Board of Directors effective as of August 16, 2026, as inducements material to Mr. Nicacio entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consisted of (i) a nonstatutory stock option to purchase up to 191,676 shares of common stock and (ii) restricted stock units for 58,333 shares of common stock. The option has an exercise price of $10.09. The option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the grant date and the remaining 75% vesting in equal monthly installments over the following 36 months, subject to Mr. Nicacio's continued service with the Company through the applicable vesting dates. Each restricted stock unit will entitle Mr. Nicacio to receive one share of the Company's common stock for each restricted stock unit that vests. The restricted stock units will vest in four equal annual installments on each anniversary of the grant date, until the fourth anniversary of such date, subject to his continued service with the Company through the applicable vesting dates.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus' pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including statements relating to the Company's equity compensation practices. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

INVESTOR CONTACTS:  
Sean Moran 
Chief Financial Officer 
Corbus Pharmaceuticals 
smoran@corbuspharma.com 

Dan Ferry 
Managing Director 
LifeSci Advisors, LLC 
daniel@lifesciadvisors.com 

MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com

FAQ

What inducement equity awards did Corbus Pharmaceuticals (CRBP) grant to its new CMO?

Corbus granted Leonardo Nicacio a nonstatutory option for 191,676 shares at $10.09 and 58,333 restricted stock units. According to Corbus, both awards were approved as inducements material to his employment under Nasdaq Listing Rule 5635(c)(4), outside stockholder-approved plans.

How do the stock options for Corbus Pharmaceuticals (CRBP) new CMO vest and what is the term?

The option has a ten-year term and vests over four years. According to Corbus, 25% of shares vest on the first anniversary, with the remaining 75% vesting in equal monthly installments over the next 36 months, subject to continued service.

What is the vesting schedule for the 58,333 RSUs granted by Corbus Pharmaceuticals (CRBP)?

The 58,333 RSUs vest in four equal annual installments. According to Corbus, each anniversary of the August 16, 2026 grant date triggers one-quarter vesting, until the fourth anniversary, contingent on Leonardo Nicacio’s continued service with the company.

Why did Corbus Pharmaceuticals (CRBP) grant equity awards outside its stockholder-approved plans?

Corbus used Nasdaq Listing Rule 5635(c)(4) to grant inducement awards outside existing plans. According to Corbus, these equity awards were a material inducement for Leonardo Nicacio to accept the Chief Medical Officer role, aligning compensation with recruitment needs and regulatory requirements.

What does the inducement grant mean for Corbus Pharmaceuticals (CRBP) shareholders in terms of dilution?

If fully vested and exercised, the 191,676 options and 58,333 RSUs could increase Corbus’ share count. According to Corbus, these awards are new equity issued as employment inducements, representing a potential future dilution for existing shareholders.

What is Corbus Pharmaceuticals’ (CRBP) clinical focus and pipeline as of August 2026?

Corbus is a clinical-stage company focused on oncology and obesity. According to Corbus, its pipeline includes CRB-701, a next-generation antibody-drug conjugate for Nectin-4-expressing tumors, and CRB-913, an oral CB1 inverse agonist candidate for obesity treatment.

Who should investors or media contact regarding the Corbus Pharmaceuticals (CRBP) inducement grants?

According to Corbus, investor contacts are Sean Moran, Chief Financial Officer, at smoran@corbuspharma.com, and Dan Ferry, Managing Director at LifeSci Advisors, at daniel@lifesciadvisors.com. Media inquiries can be directed to Liz Melone at liz@melonecomm.com.